Assessing the clinical utility of cancer genomic and proteomic data across tumor types

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma

(2013) H.W.Z. Khella et al.   CARCINOGENESIS

Characteristics of Lung Cancers Harboring NRAS Mutations

(2013) K. Ohashi et al.   CLINICAL CANCER RESEARCH

Clinical Analysis and Interpretation of Cancer Genome Data

(2013) Eliezer M. Van Allen et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomics-Driven Oncology: Framework for an Emerging Paradigm

(2013) Levi A. Garraway   JOURNAL OF CLINICAL ONCOLOGY

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

(2013) Daniel YC Heng et al.   LANCET ONCOLOGY

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer

(2013) A. A. Margolin et al.   Science Translational Medicine

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling

(2013) Erhan Bilal et al.   PLoS Computational Biology

The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells

(2012) Toshihiko Sakurai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Predicting the lethal phenotype of the knockout mouse by integrating comprehensive genomic data

(2012) Yuan Yuan et al.   BIOINFORMATICS

MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma

(2012) Yang Ni et al.   GENE

Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting

(2012) Lisa M. McShane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma

(2012) Hala Faragalla et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

(2012) Matthias Holdhoff et al.   JOURNAL OF NEURO-ONCOLOGY

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival

(2012) Mohd Saif Zaman et al.   PLoS One

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance

(2012) James W. Antoon et al.   Scientific Reports

Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc

(2011) Yongchao Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells

(2011) Syunsuke Noguchi et al.   CANCER LETTERS

A microRNA survival signature (MiSS) for advanced ovarian cancer

(2011) Karin K. Shih et al.   GYNECOLOGIC ONCOLOGY

Glioblastoma survival in the United States before and during the temozolomide era

(2011) Derek R. Johnson et al.   JOURNAL OF NEURO-ONCOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer

(2011) Shuli Liang et al.   PLoS One

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

(2011) Nikhil Wagle et al.   Cancer Discovery

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Current and emerging biomarkers in breast cancer: prognosis and prediction

(2010) Marion T Weigel et al.   ENDOCRINE-RELATED CANCER

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

(2010)   NATURE BIOTECHNOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

(2009) Laura E. MacConaill et al.   PLoS One

Random survival forests

(2008) Hemant Ishwaran et al.   Annals of Applied Statistics

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

(2008) C. M. Sturgeon et al.   CLINICAL CHEMISTRY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE